Comparison of Body Composition Changes With Weight Loss Interventions
NCT07115069 · Recruiting
Last updated 2026-05-28This clinical trial compares how different weight loss methods affect muscle loss in adults with obesity.
What this study is testing ClinicalTrials.gov NCT07115069 ↗
Description as written by the study sponsor.
This study is being done to compare the effects of a newer class of weight loss medications to weight loss surgery on the body's muscle, metabolism, and side effects over time. People with severe obesity often lose weight using either medications like GLP-1 receptor agonists (such as semaglutide or tirzepatide) or by having bariatric surgery, such as gastric bypass. While both approaches can lead to weight loss, they may affect the body in different ways. The investigators are inviting adult patients who are planning to either start one of these weight loss medications or undergo gastric bypass surgery to join this study. Participants will be asked to complete four body composition scans (called DXA scans) over the course of a year-at the beginning of the study and again at 3, 6, and 12 months. These scans will help us measure changes in fat and muscle. Participants will also complete surveys and provide information on side effects, such as nausea or fatigue, that may affect their eating or activity levels. The investigators' goal is to better understand how different weight loss treatments impact not just weight, but also muscle mass, energy levels, and side effects. This information may help doctors and patients choose the most appropriate treatment in the future.
Treatments tested
- GLP-1 receptor agonist also known as semaglutide, tirzepatide Drug
Any FDA-approved GLP-1 receptor agonist
- Gastric Bypass Surgery (laparoscopic) also known as RNYGB Procedure
Patients undergo laparoscopic gastric bypass with a roux limb between 75 - 150 cm and biliopancreatic limb between 50 - 150 cm as determined by the primary surgeon.
- Gastric Bypass Surgery (robotic) also known as RNYGB Procedure
Patients undergo robotic gastric bypass with a roux limb between 75 - 150 cm and biliopancreatic limb between 50 - 150 cm as determined by the primary surgeon.
| Main thing measured | Skeletal Muscle Loss |
|---|---|
| Sponsor | Vanderbilt University Medical Center |
| Conditions studied | Obesity |
| GLP-1 drugs | — |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07115069 ↗